Cervical cancer continues to be listed among the top gynecologic cancers worldwide. According to current data, it is ranked fourteenth among all cancers and fourth-ranked cancer among women worldwide.[1] Cervical cancer intervention focuses on primary and secondary prevention. [2] Primary prevention and screening is the best method to decrease the burden of cervical cancer and to decrease mortality.
Targeted education, screening, and intervention can reduce the burden of disease. Like many diseases and cancers, disparities exist in screening rates, early diagnosis, and timely treatment. Screening rates tend to be less in low socioeconomic and low resource areas with ethnic and age variations. Studies show that women with obesity and chronic disease may also have lower rates of cervical and breast cancer screening. A study on ethnic minority women in the United Kingdom reports several barriers to screening including lack of awareness, fear, embarrassment, and shame, and low perceived risk.[3] One study reviewing the barriers for Haitian women revealed socioeconomic barriers, language barriers, and limited understanding of health and disease. [4] In the United States, cervical cancer mortality is disproportionately higher for African American women. Since 2006, HPV vaccinations have been available for the prevention of cervical cancer. Vaccination can improve cancer death rates in underdeveloped countries where resources may not be available for routine screening and in populations with higher mortality rates.
People with cervical cancer may experience physical, emotional and spiritual symptoms. Cancer treatments such as radiation and chemotherapy may cause side effects including nausea, vomiting, pain, dysuria, diarrhea, fatigue, neutropenia, and more. Examples of Nursing Diagnoses that may be utilized for people with cervical cancer include, but are not limited to:
Cervical cancer is caused by the Human papillomavirus (HPV). Current literature reports HPV is found in the majority of sexually active people at some point during their life. There are more than 130 types of known HPV with 20 HPV types identified as cancer-related. HPV-related cervical dysplasia rates are only known in women since men are not screened outside of research protocols. HPV 16 and 18 are the most commonly found HPV in invasive cervical cancer. Population-based HPV prevalence studies show that the greatest prevalence of high-risk HPV occurs in the young adult period before 25 years of life and cervical cancer death peaks in the middle age period of 40 to 50 years of life. Studies have shown that HPV-related cervical disease in women younger than 25 years old is largely self-limiting. However, those with other genital infections may be less likely to have spontaneous clearance and progress to cancer.
Risk factors for HPV and cervical cancer include age at first intercourse, multiple sexual partners, smoking, herpes simplex, HIV, co-infection with other genital infections, and oral contraceptive use. HPV is transmitted by skin-to-skin contact including during sexual intercourse, hand to genital organ contact, and oral sex.[5][6] Approximately 250,000 women worldwide die of cervical cancer annually. In the United States, about 4000 women die from cervical cancer annually with African Americans, Hispanics, and women in low-resource areas having higher disparities in evidence-based care and a much higher mortality rate.[7][8] Cervical cancer mortality is higher among women who have not been screened in the last five years and those women without consistent follow-up post identification of a precancerous lesion. Trends continue to show that women with the highest risk of mortality may be less likely to receive a vaccination that could potentially prevent cervical cancer.
In the United States and other developing countries, most screening and diagnostic efforts are directed towards the early identification of high-risk human papillomavirus (HPV) lesions through HPV testing and Pap smears. Although HPV testing is not recommended in women younger than 30 years of age, low-risk younger women should begin screening with Pap tests at age 21 and continue until age 65, according to the United States Preventive Services Task Force recommendations. Newer recommendations offer 3 to 5-year intervals between screening based on prior results and the use of pap and HPV co-testing. [9][10]
The patient with cervical cancer is usually asymptomatic in the early stages. The history and physical involve a thorough sexual history including first age of intercourse, postcoital bleeding, and if there is pain during intercourse. Other pertinent information to gather includes previous sexually transmitted infections, the number of lifetime partners, previous history of HPV infection, history of human immunodeficiency virus, use of tobacco, and whether the patient has had a previous vaccination against HPV. The interview should also include menstrual patterns and any abnormal bleeding, persistent vaginal discharges, irritations, or known cervical lesions. The physical exam must include a full evaluation of the external and internal genitalia. In women with cervical cancer, the exam findings might include a friable cervix, lesions, erosions, or bleeding with examination and fixed adnexa.
According to the United States Preventative Services Task Force (USPTF), Pap screening is recommended beginning at age 21 years of age. HPV testing begins at age 30 in conjunction with Pap smear cytology. Screening is recommended every three years for women with continued normal screening and those low risk for cervical cancer. For women over 30 years of age, cytology can be every five years with HPV testing. [Level A] The recommendation for women with low-risk status and consistent normal screenings can discontinue cervical cancer cytology and HPV testing at age 65. Women who have had a total abdominal hysterectomy including removal of the cervix for benign disease do not require further screening.[10]
Precancerous lesions are managed conservatively for those women younger than 25 years. The majority of abnormal findings in women younger than 25 are low-risk cervical dysplasia and will resolve spontaneously. Colposcopy evaluates persistent, abnormal cytology or lesions suspected to be greater than low risk. These are managed according to findings. Low-risk lesions may be watched and reevaluated more frequently, and high-risk lesions are treated based on size, location, and staging. Cryotherapy or excision is done to manage pre-cancerous lesions that are limited in size and depth. Conization, laser or Loop Electrosurgical Excision Procedure (LEEP) are used in managing those lesions that include the endocervical canal and are more extensive. LEEP may provide better visualization of the squamocolumnar junction and provide the benefit of less bleeding in the outpatient setting. [11]
If cancer is diagnosed, the next step in management is staging to determine further treatment. Staging is based on findings and results from examination, tissue findings, imaging, and reported signs and symptoms. Grading is based on the size and depth of cancer and signs of spread to other organs. Curative treatments for patients with cervical cancer include surgery such as radical hysterectomy, chemotherapy, radiation, or a combination of these modalities. The plan of care is individualized to the patient's cancer stage and the patient's desire to conserve fertility[12].
Oncology nurses are important in the patient's health care team, providing support, education, and connecting patients with resources. Nurses are involved in the care of the patient in many different settings:
In these various settings, nurses can educate cervical cancer patients on the importance of adhering to treatment schedules, anticipated side effects, and how to manage them. Nurses also have the opportunity to educate patients on HPV vaccinations and regular cancer screenings in efforts of primary and secondary prevention.
Nurses may need to follow lab results and report any abnormal findings, especially with white blood cell and red blood cell counts. Patients are at risk for neutropenia and anemia when receiving chemotherapy and if experiencing any bleeding. Patients undergoing radiation therapy may need skincare guidance. Potential side effects of treatment are nausea, vomiting, and diarrhea, so it is also important to monitor lab values and vital signs for signs of dehydration or electrolyte imbalance.
Patients should be advised to seek help immediately for heavy bleeding, feelings of dizziness or fainting, uncontrolled pain, fevers, or new swelling of the extremities.
Nurses collaborate regularly with primary gynecologists and oncologists, pharmacists, radiation therapists, social workers, chaplains, and other specialists to ensure the patient's holistic needs are met during cancer treatment and survivorship. Oncology nurse navigators can have positive effects on patient satisfaction and help patients navigate systems-level barriers to receiving timely and coordinated care. [13]
Both traditional methods of patient education and innovative methods can increase awareness of cervical cancer and the need for prevention and early screening. [14][15] The literature shows that doctors may not be recommending or discussing HPV vaccination with patients. Women and parents also have vaccination fears. In high-risk populations, additional education by providers and nurses may increase awareness, prevention, and screening among those women at risk for the highest mortality.[16] Culturally sensitive information, appropriate language to reach low health literacy populations, and targeted efforts to women not yet sexually active are strategies needed to expand patient education and awareness of cervical cancer prevention and screening beyond the clinical setting through community outreach. [17][18]
Most cervical cancer treatments can be received as outpatients. Patients on active treatment should be educated about the side effects and symptoms to report. For instance, patients receiving chemotherapy should be educated about the potential for infection and when to report signs to the provider, as well as how to manage nausea. Patients receiving radiation therapy may need to know about expected side effects including dysuria, diarrhea, skin changes, and fatigue. After treatment is complete, a follow-up plan should be clearly communicated with the patients. Transitioning to survivorship may be an increased time of vulnerability for people with cancer, so nurses can play an important role in providing support and other resources.
Cervical cancer is the four ranked cancer among women worldwide. Cervical cancer is caused by the human papillomavirus (HPV) which is a sexually transmitted viral infection found in most adults during their lifetime. Primary and secondary prevention is key with cervical cancer, including HPV vaccination and regular cervical cancer and HPV screening. Treatment for cervical cancer includes surgery, radiation therapy, and/or chemotherapy. People with cervical cancer may be asymptomatic in the early stages, but often present for workup with vaginal bleeding and pain with sexual intercourse. During treatment, people with cervical cancer may experience treatment side effects such as nausea, vomiting, dysuria, diarrhea, neutropenia, skin irritation, and more. Nurses play an important role in symptom management and coordination of care during a person's journey through cancer diagnosis, treatment, and survivorship.
Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. The Lancet. Oncology. 2019 Mar:20(3):319-321. doi: 10.1016/S1470-2045(19)30072-5. Epub 2019 Feb 19 [PubMed PMID: 30795952]
Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva ginecologica. 2019 Aug:71(4):313-320. doi: 10.23736/S0026-4784.19.04397-1. Epub 2019 Feb 22 [PubMed PMID: 30808155]
. Cervical Cancer Screening Every 5 Years OK. Cancer discovery. 2018 Oct:8(10):1204. doi: 10.1158/2159-8290.CD-NB2018-118. Epub 2018 Sep 11 [PubMed PMID: 30206109]
Farghaly H, Bourgeois D, Houser PM, Padmanabhan V, Lage JM, Hoda RS. Routine vaginal Pap test is not useful in women status-post hysterectomy for benign disease. Diagnostic cytopathology. 2006 Sep:34(9):640-3 [PubMed PMID: 16900480]
Foran C, Brennan A. Prevention and early detection of cervical cancer in the UK. British journal of nursing (Mark Allen Publishing). 2015 May 28-Jun 10:24(10):S22-4, S26, S28-9. doi: 10.12968/bjon.2015.24.Sup10.S22. Epub [PubMed PMID: 26018178]
Pierre-Victor D, Stephens DP, Omondi A, Clarke R, Jean-Baptiste N, Madhivanan P. Barriers to HPV Vaccination Among Unvaccinated, Haitian American College Women. Health equity. 2018:2(1):90-97. doi: 10.1089/heq.2017.0028. Epub 2018 Jun 1 [PubMed PMID: 29904749]
Manini I, Montomoli E. Epidemiology and prevention of Human Papillomavirus. Annali di igiene : medicina preventiva e di comunita. 2018 Jul-Aug:30(4 Supple 1):28-32. doi: 10.7416/ai.2018.2231. Epub [PubMed PMID: 30062377]
Ghosh I, Mandal R, Kundu P, Biswas J. Association of Genital Infections Other Than Human Papillomavirus with Pre-Invasive and Invasive Cervical Neoplasia. Journal of clinical and diagnostic research : JCDR. 2016 Feb:10(2):XE01-XE06. doi: 10.7860/JCDR/2016/15305.7173. Epub 2016 Feb 1 [PubMed PMID: 27042571]
Kuhn L, Denny L. The time is now to implement HPV testing for primary screening in low resource settings. Preventive medicine. 2017 May:98():42-44. doi: 10.1016/j.ypmed.2016.12.030. Epub 2017 Feb 6 [PubMed PMID: 28279263]
Rauh-Hain JA, Melamed A, Schaps D, Bregar AJ, Spencer R, Schorge JO, Rice LW, Del Carmen MG. Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies. Gynecologic oncology. 2018 Apr:149(1):4-11. doi: 10.1016/j.ygyno.2017.12.006. Epub [PubMed PMID: 29605048]
Wang X, Huang X, Zhang Y. Involvement of Human Papillomaviruses in Cervical Cancer. Frontiers in microbiology. 2018:9():2896. doi: 10.3389/fmicb.2018.02896. Epub 2018 Nov 28 [PubMed PMID: 30546351]
Senol T, Polat M, Ozkaya E, Karateke A. Comparison of Two Step LEEP and Cold Conisation For Cervical Intraepithelial Lesions to Decrease Positive Surgical Margins. Asian Pacific journal of cancer prevention : APJCP. 2016:17(7):3317-20 [PubMed PMID: 27509969]
Shachner TR, Van Meter SE. Metastatic melanoma of the uterine cervix diagnosed on cervical Pap smear: Case report and literature review. Diagnostic cytopathology. 2018 Dec:46(12):1045-1049. doi: 10.1002/dc.24058. Epub 2018 Oct 24 [PubMed PMID: 30354020]
Larsson G, Gullberg B, Grundsell H. A comparison of complications of laser and cold knife conization. Obstetrics and gynecology. 1983 Aug:62(2):213-7 [PubMed PMID: 6408545]
Brun JL, Youbi A, Hocké C. [Complications, sequellae and outcome of cervical conizations: evaluation of three surgical technics]. Journal de gynecologie, obstetrique et biologie de la reproduction. 2002 Oct:31(6):558-64 [PubMed PMID: 12407327]
Smith ES, Moon AS, O'Hanlon R, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Mueller JJ. Radical Trachelectomy for the Treatment of Early-Stage Cervical Cancer: A Systematic Review. Obstetrics and gynecology. 2020 Sep:136(3):533-542. doi: 10.1097/AOG.0000000000003952. Epub [PubMed PMID: 32769648]
Cibula D, Abu-Rustum NR, Benedetti-Panici P, Köhler C, Raspagliesi F, Querleu D, Morrow CP. New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. Gynecologic oncology. 2011 Aug:122(2):264-8. doi: 10.1016/j.ygyno.2011.04.029. Epub 2011 May 17 [PubMed PMID: 21592548]
Querleu D, Morrow CP. Classification of radical hysterectomy. The Lancet. Oncology. 2008 Mar:9(3):297-303. doi: 10.1016/S1470-2045(08)70074-3. Epub [PubMed PMID: 18308255]
Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. The New England journal of medicine. 2018 Nov 15:379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31 [PubMed PMID: 30380365]
Lécuru F, Mathevet P, Querleu D, Leblanc E, Morice P, Daraï E, Marret H, Magaud L, Gillaizeau F, Chatellier G, Dargent D. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 May 1:29(13):1686-91. doi: 10.1200/JCO.2010.32.0432. Epub 2011 Mar 28 [PubMed PMID: 21444878]
Mathevet P, Lécuru F, Uzan C, Boutitie F, Magaud L, Guyon F, Querleu D, Fourchotte V, Baron M, Bats AS, Senticol 2 group. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2). European journal of cancer (Oxford, England : 1990). 2021 May:148():307-315. doi: 10.1016/j.ejca.2021.02.009. Epub 2021 Mar 24 [PubMed PMID: 33773275]
Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. The Lancet. Oncology. 2006 Oct:7(10):837-47 [PubMed PMID: 17012046]
Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, Ramondetta LM, Bodurka DC, Ramirez PT, Soliman PT. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecologic oncology. 2014 Sep:134(3):546-51. doi: 10.1016/j.ygyno.2014.06.034. Epub 2014 Jul 9 [PubMed PMID: 25014540]
Magrina JF, Stanhope CR, Weaver AL. Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecologic oncology. 1997 Jan:64(1):130-5 [PubMed PMID: 8995561]
Bourke J, Wong K, Srinivasjois R, Pereira G, Shepherd CCJ, White SW, Stanley F, Leonard H. Predicting Long-Term Survival Without Major Disability for Infants Born Preterm. The Journal of pediatrics. 2019 Dec:215():90-97.e1. doi: 10.1016/j.jpeds.2019.07.056. Epub 2019 Sep 4 [PubMed PMID: 31493909]
Zanotti-Fregonara P, Laforest R, Wallis JW. Fetal Radiation Dose from 18F-FDG in Pregnant Patients Imaged with PET, PET/CT, and PET/MR. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Aug:56(8):1218-22. doi: 10.2967/jnumed.115.157032. Epub 2015 Jun 18 [PubMed PMID: 26089550]
Alouini S, Rida K, Mathevet P. Cervical cancer complicating pregnancy: implications of laparoscopic lymphadenectomy. Gynecologic oncology. 2008 Mar:108(3):472-7. doi: 10.1016/j.ygyno.2007.12.006. Epub 2008 Jan 16 [PubMed PMID: 18201752]
Bernardini F, Ferrandina G, Ricci C, Fagotti A, Fanfani F, Cavaliere AF, Gui B, Scambia G, De Vincenzo R. Neoadjuvant Chemotherapy in Pregnant Patients with Cervical Cancer: A Monocentric Retrospective Study. Current oncology (Toronto, Ont.). 2022 Aug 14:29(8):5702-5714. doi: 10.3390/curroncol29080450. Epub 2022 Aug 14 [PubMed PMID: 36005188]
Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (London, England). 1997 Aug 23:350(9077):535-40 [PubMed PMID: 9284774]
Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. Journal of gynecologic oncology. 2017 May:28(3):e34. doi: 10.3802/jgo.2017.28.e34. Epub 2017 Feb 24 [PubMed PMID: 28382797]
Stehman FB,Ali S,Keys HM,Muderspach LI,Chafe WE,Gallup DG,Walker JL,Gersell D, Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. American journal of obstetrics and gynecology. 2007 Nov [PubMed PMID: 17980189]
Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. The New England journal of medicine. 1999 Apr 15:340(15):1137-43 [PubMed PMID: 10202164]
Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecologic oncology. 1999 May:73(2):177-83 [PubMed PMID: 10329031]
Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, Kelly MG, Tewari KS, McNally L, Guntupalli SR, Ragab O, Lee YC, Miller DS, Huh WK, Wilkinson KJ, Spirtos NM, Van Le L, Casablanca Y, Holman LL, Waggoner SE, Fader AN. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecologic oncology. 2021 Sep:162(3):532-538. doi: 10.1016/j.ygyno.2021.06.017. Epub 2021 Jul 1 [PubMed PMID: 34217544]
Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Apr:18(8):1606-13 [PubMed PMID: 10764420]
Huang H, Feng YL, Wan T, Zhang YN, Cao XP, Huang YW, Xiong Y, Huang X, Zheng M, Li YF, Li JD, Chen GD, Li H, Chen YL, Ma LG, Yang HY, Li L, Yao SZ, Ye WJ, Tu H, Huang QD, Liang LZ, Liu FY, Liu Q, Liu JH. Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial. JAMA oncology. 2021 Mar 1:7(3):361-369. doi: 10.1001/jamaoncol.2020.7168. Epub [PubMed PMID: 33443541]
Mell LK, Sirák I, Wei L, Tarnawski R, Mahantshetty U, Yashar CM, McHale MT, Xu R, Honerkamp-Smith G, Carmona R, Wright M, Williamson CW, Kasaová L, Li N, Kry S, Michalski J, Bosch W, Straube W, Schwarz J, Lowenstein J, Jiang SB, Saenz CC, Plaxe S, Einck J, Khorprasert C, Koonings P, Harrison T, Shi M, Mundt AJ, INTERTECC Study Group. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2). International journal of radiation oncology, biology, physics. 2017 Mar 1:97(3):536-545. doi: 10.1016/j.ijrobp.2016.11.027. Epub 2016 Nov 23 [PubMed PMID: 28126303]
Yeung AR, Pugh SL, Klopp AH, Gil KM, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Bruner DW, Kachnic LA. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 May 20:38(15):1685-1692. doi: 10.1200/JCO.19.02381. Epub 2020 Feb 19 [PubMed PMID: 32073955]
Gonzalez VJ, Hullett CR, Burt L, Rassiah-Szegedi P, Sarkar V, Tward JD, Hazard LJ, Huang YJ, Salter BJ, Gaffney DK. Impact of prone versus supine positioning on small bowel dose with pelvic intensity modulated radiation therapy. Advances in radiation oncology. 2017 Apr-Jun:2(2):235-243. doi: 10.1016/j.adro.2017.01.005. Epub 2017 Jan 24 [PubMed PMID: 28740937]
Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M. Radiation dose-volume effects in the stomach and small bowel. International journal of radiation oncology, biology, physics. 2010 Mar 1:76(3 Suppl):S101-7. doi: 10.1016/j.ijrobp.2009.05.071. Epub [PubMed PMID: 20171503]
Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012 Jan-Feb:11(1):33-46. doi: 10.1016/j.brachy.2011.07.003. Epub [PubMed PMID: 22265436]
Viswanathan AN, Beriwal S, De Los Santos JF, Demanes DJ, Gaffney D, Hansen J, Jones E, Kirisits C, Thomadsen B, Erickson B, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012 Jan-Feb:11(1):47-52. doi: 10.1016/j.brachy.2011.07.002. Epub [PubMed PMID: 22265437]
Charra-Brunaud C, Harter V, Delannes M, Haie-Meder C, Quetin P, Kerr C, Castelain B, Thomas L, Peiffert D. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012 Jun:103(3):305-13. doi: 10.1016/j.radonc.2012.04.007. Epub 2012 May 25 [PubMed PMID: 22633469]
Pötter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza AE, Hoskin P, Mahantshetty U, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Tan LT, Nout RA, De Leeuw AAC, Ristl R, Petric P, Nesvacil N, Kirchheiner K, Kirisits C, Lindegaard JC, EMBRACE Collaborative Group. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. The Lancet. Oncology. 2021 Apr:22(4):538-547. doi: 10.1016/S1470-2045(20)30753-1. Epub [PubMed PMID: 33794207]
Dimopoulos JC, Petrow P, Tanderup K, Petric P, Berger D, Kirisits C, Pedersen EM, van Limbergen E, Haie-Meder C, Pötter R. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012 Apr:103(1):113-22. doi: 10.1016/j.radonc.2011.12.024. Epub 2012 Jan 30 [PubMed PMID: 22296748]
. Report 89. Journal of the ICRU. 2013 Apr:13(1-2):NP. doi: 10.1093/jicru/ndw042. Epub [PubMed PMID: 27335498]
Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Šegedin B, Mahantshetty U, Hoskin P, Jürgenliemk-Schulz I, Kirisits C, Lindegaard JC, Dörr W, Haie-Meder C, Tanderup K, Pötter R, EMBRACE collaborative group. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016 Sep:120(3):412-419. doi: 10.1016/j.radonc.2016.06.006. Epub 2016 Jul 7 [PubMed PMID: 27396811]
Lucidarme D, Marteau P, Foucault M, Vautrin B, Filoche B. Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Alimentary pharmacology & therapeutics. 1997 Apr:11(2):335-40 [PubMed PMID: 9146772]
Rigaud J, Hetet JF, Bouchot O. [Management of radiation cystitis]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2004 Sep:14(4):568-72 [PubMed PMID: 15776916]
Pereira D, Ferreira C, Catarino R, Correia T, Cardoso A, Reis F, Cerqueira M, Prisco R, Camacho O. Hyperbaric oxygen for radiation-induced cystitis: A long-term follow-up. Actas urologicas espanolas. 2020 Oct:44(8):561-567. doi: 10.1016/j.acuro.2020.03.010. Epub 2020 Jul 28 [PubMed PMID: 32736899]
Boice JD Jr, Day NE, Andersen A, Brinton LA, Brown R, Choi NW, Clarke EA, Coleman MP, Curtis RE, Flannery JT. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. Journal of the National Cancer Institute. 1985 May:74(5):955-75 [PubMed PMID: 3858584]
Wright JD, St Clair CM, Deutsch I, Burke WM, Gorrochurn P, Sun X, Herzog TJ. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer. 2010 May 15:116(10):2486-92. doi: 10.1002/cncr.25067. Epub [PubMed PMID: 20209618]
Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. International journal of radiation oncology, biology, physics. 2005 Jul 1:62(3):738-44 [PubMed PMID: 15936554]
Small W Jr, Kim YS, Joyce C, Surucu M, Leshyk M, Harkenrider MM, Potkul RK, Liotta M, Winder A, Altoos B. Uterine perforation during brachytherapy for cervical cancer: Complications, outcomes, and best practices for forward treatment planning and management. Brachytherapy. 2021 May-Jun:20(3):557-564. doi: 10.1016/j.brachy.2021.02.001. Epub 2021 Mar 17 [PubMed PMID: 33741275]
van Dyk S, Schneider M, Kondalsamy-Chennakesavan S, Bernshaw D, Narayan K. Ultrasound use in gynecologic brachytherapy: Time to focus the beam. Brachytherapy. 2015 May-Jun:14(3):390-400. doi: 10.1016/j.brachy.2014.12.001. Epub 2015 Jan 22 [PubMed PMID: 25620161]
Rowlands S, Oloto E, Horwell DH. Intrauterine devices and risk of uterine perforation: current perspectives. Open access journal of contraception. 2016:7():19-32. doi: 10.2147/OAJC.S85546. Epub 2016 Mar 16 [PubMed PMID: 29386934]
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. The New England journal of medicine. 1999 Apr 15:340(15):1144-53 [PubMed PMID: 10202165]
Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 May 1:29(13):1678-85. doi: 10.1200/JCO.2009.25.9663. Epub 2011 Mar 28 [PubMed PMID: 21444871]
Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Aug 1:22(15):3113-9 [PubMed PMID: 15284262]
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Oct 1:27(28):4649-55. doi: 10.1200/JCO.2009.21.8909. Epub 2009 Aug 31 [PubMed PMID: 19720909]
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet (London, England). 2017 Oct 7:390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27 [PubMed PMID: 28756902]
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 1:38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4 [PubMed PMID: 31682550]
Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ, KEYNOTE-826 Investigators. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. The New England journal of medicine. 2021 Nov 11:385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18 [PubMed PMID: 34534429]
Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jul 1:33(19):2129-35. doi: 10.1200/JCO.2014.58.4391. Epub 2015 Mar 2 [PubMed PMID: 25732161]
Salib MY, Russell JHB, Stewart VR, Sudderuddin SA, Barwick TD, Rockall AG, Bharwani N. 2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging. Radiographics : a review publication of the Radiological Society of North America, Inc. 2020 Oct:40(6):1807-1822. doi: 10.1148/rg.2020200013. Epub 2020 Sep 18 [PubMed PMID: 32946322]
Spinner C, Ding L, Bernstein DI, Brown DR, Franco EL, Covert C, Kahn JA. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics. 2019 Feb:143(2):. doi: 10.1542/peds.2018-1902. Epub 2019 Jan 22 [PubMed PMID: 30670582]
Castellano T, Ding K, Moore KN, Landrum LM. Simple Hysterectomy for Cervical Cancer: Risk Factors for Failed Screening and Deviation From Screening Guidelines. Journal of lower genital tract disease. 2019 Apr:23(2):124-128. doi: 10.1097/LGT.0000000000000463. Epub [PubMed PMID: 30817687]
Rauh-Hain JA, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman A, Boruta DM 2nd, Schorge JO, del Carmen MG. Racial disparities in cervical cancer survival over time. Cancer. 2013 Oct 15:119(20):3644-52. doi: 10.1002/cncr.28261. Epub 2013 Jul 31 [PubMed PMID: 23913530]
Pergialiotis V, Bellos I, Thomakos N, Haidopoulos D, Perrea DN, Kontzoglou K, Daskalakis G, Rodolakis A. Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature. Oncology reviews. 2019 Jan 14:13(1):387. doi: 10.4081/oncol.2019.387. Epub 2019 Jan 15 [PubMed PMID: 30746036]
Mendu S, Boukhechba M, Gordon JR, Datta D, Molina E, Arroyo G, Proctor SK, Wells KJ, Barnes LE. Design of a Culturally-Informed Virtual Human for Educating Hispanic Women about Cervical Cancer. International Conference on Pervasive Computing Technologies for Healthcare : [proceedings]. International Conference on Pervasive Computing Technologies for Healthcare. 2018 May:2018():360-366. doi: 10.1145/3240925.3240968. Epub [PubMed PMID: 30555731]
Nasser S, Berek J, Ullrich A, Giordano L, Sehouli J. A report on the Marrakech International Women's Cancer Days: dialogs and implications. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2019 Feb:29(2):417-421. doi: 10.1136/ijgc-2018-000059. Epub 2018 Dec 21 [PubMed PMID: 30718317]
Cunningham-Erves J, Forbes L, Ivankova N, Mayo-Gamble T, Kelly-Taylor K, Deakings J. Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication. Gynecologic oncology. 2018 Jun:149(3):506-512. doi: 10.1016/j.ygyno.2018.03.047. Epub 2018 Mar 24 [PubMed PMID: 29588103]
Mabelele MM, Materu J, Ng'ida FD, Mahande MJ. Knowledge towards cervical cancer prevention and screening practices among women who attended reproductive and child health clinic at Magu district hospital, Lake Zone Tanzania: a cross-sectional study. BMC cancer. 2018 May 16:18(1):565. doi: 10.1186/s12885-018-4490-7. Epub 2018 May 16 [PubMed PMID: 29769124]
Lai D, Bodson J, Davis FA, Lee D, Tavake-Pasi F, Napia E, Villalta J, Mukundente V, Mooney R, Coulter H, Stark LA, Sanchez-Birkhead AC, Kepka D. Diverse Families' Experiences with HPV Vaccine Information Sources: A Community-Based Participatory Approach. Journal of community health. 2017 Apr:42(2):400-412. doi: 10.1007/s10900-016-0269-4. Epub [PubMed PMID: 27734247]
Bayu H, Berhe Y, Mulat A, Alemu A. Cervical Cancer Screening Service Uptake and Associated Factors among Age Eligible Women in Mekelle Zone, Northern Ethiopia, 2015: A Community Based Study Using Health Belief Model. PloS one. 2016:11(3):e0149908. doi: 10.1371/journal.pone.0149908. Epub 2016 Mar 10 [PubMed PMID: 26963098]
Kung TH, Gordon JR, Abdullahi A, Barve A, Chaudhari V, Kosambiya JK, Kumar A, Gamit S, Wells KJ. "My husband says this: If you are alive, you can be someone…": Facilitators and barriers to cervical cancer screening among women living with HIV in India. Cancer causes & control : CCC. 2019 Apr:30(4):365-374. doi: 10.1007/s10552-019-01145-7. Epub 2019 Feb 26 [PubMed PMID: 30809741]
McPherson GS, Fairbairn-Dunlop P, Payne D. Overcoming Barriers to Cervical Screening Among Pacific Women: A Narrative Review. Health equity. 2019:3(1):22-29. doi: 10.1089/heq.2018.0076. Epub 2019 Feb 14 [PubMed PMID: 30783634]
Romero-Masters JC, Lambert PF, Munger K. Molecular Mechanisms of MmuPV1 E6 and E7 and Implications for Human Disease. Viruses. 2022 Sep 28:14(10):. doi: 10.3390/v14102138. Epub 2022 Sep 28 [PubMed PMID: 36298698]
Mirpour S, Mhlanga JC, Logeswaran P, Russo G, Mercier G, Subramaniam RM. The role of PET/CT in the management of cervical cancer. AJR. American journal of roentgenology. 2013 Aug:201(2):W192-205. doi: 10.2214/AJR.12.9830. Epub [PubMed PMID: 23883234]
Li RZ, Sun LF, Li R, Wang HJ. Survival after minimally invasive radical hysterectomy without using uterine manipulator for early-stage cervical cancer: A systematic review and meta-analysis. BJOG : an international journal of obstetrics and gynaecology. 2023 Jan:130(2):176-183. doi: 10.1111/1471-0528.17339. Epub 2022 Nov 13 [PubMed PMID: 36331008]
Bogani G, Di Donato V, Scambia G, Raspagliesi F, Chiantera V, Sozzi G, Golia D'Augè T, Muzii L, Benedetti Panici P, D'Oria O, Vizza E, Giannini A, On Behalf Of The Investigators Of The Italian Gynecological Cancer Study Group. Radical Hysterectomy for Early Stage Cervical Cancer. International journal of environmental research and public health. 2022 Sep 15:19(18):. doi: 10.3390/ijerph191811641. Epub 2022 Sep 15 [PubMed PMID: 36141917]
Touhami O, Plante M. Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned? Current oncology (Toronto, Ont.). 2022 Feb 14:29(2):1093-1106. doi: 10.3390/curroncol29020093. Epub 2022 Feb 14 [PubMed PMID: 35200592]